1172127-74-0

Basic information

• Product Name: 5-chloro-4-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 1172127-74-0
• Molecular Weight: 361.785
• Mol File: 1172127-74-0.mol

Chemical Properties

• CAS DataBase Reference: 5-chloro-4-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-4-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine(1172127-74-0)
• EPA Substance Registry System: 5-chloro-4-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine(1172127-74-0)

Safety Data

• Hazardous Substances Data: 1172127-74-0(Hazardous Substances Data)

Upstream product

• 1172128-13-0 5-chloro-4-phenyl-7-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents

A series of novel 7-deazapurine ribonucleosides bearing an alkyl, aryl, or hetaryl group in position 6 and H, F, or Cl atom in position 7 has been prepared either by Pd-catalyzed cross-coupling reactions of the corresponding protected 6-chloro-(7-halogenated-)7-deazapurine ribonucleosides with alkyl- or (het)-arylorganometallics followed by deprotection, or by single-step aqueous phase cross-coupling reactions of unprotected 6-chloro-(7-halogenated-)7- deazapurine ribonucleosides with (het)arylboronic acids. Significant cytostatic effect was detected with a substantial proportion of the prepared compounds. The most potent were 7-H or 7-F derivatives of 6-furyl- or 6-thienyl-7-deazapurines displaying cytostatic activity in multiple cancer cell lines with a geometric mean of 50% growth inhibition concentration ranging from 16 to 96 nM, a potency comparable to or better than that of the nucleoside analogue clofarabine. Intracellular phosphorylation to mono- and triphosphates and the inhibition of total RNA synthesis was demonstrated in preliminary study of metabolism and mechanism of action studies. 2009 American Chemical Society.

NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES

The invention provides compounds of formula (I), wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.